The majority of diagnosed cancers have no recommended screening available. The TruCheck multi-cancer early detection test helps bridge this gap by detecting more than 70 types of cancer from a single blood test.
The TruCheck test can increase your likelihood of identifying signals associated with cancer at an early stage. Early detection significantly increases your chances of recovery.
Only 5 recommended cancer screening tests exist today2:
breast, colorectal, lung (for those at risk), cervical, and prostate
About 3 out of 4 new cancer cases and cancer-related deaths
will be due to cancers with no recommended screening.5
The TruCheck test looks for signals related to active cancer and does not predict your future genetic predisposition for cancer.
TruCheck is a pioneering multi-cancer early detection test—a test that identifies signals associated with a broad range of cancer types using a single blood sample. It operates as a screening tool and does not diagnose cancer; further diagnostic testing is essential for cancer confirmation.
The primary risk factor for cancer is age. Individuals over the age of 50 are 13 times more likely to develop cancer compared to those under 50. As we age, the risk of cancer increases for everyone, regardless of family history—only 5% to 10% of cancers are inherited.
The TruCheck test is advised for use in adults with an elevated risk for cancer, such as those aged 50 or older. It is designed to supplement, not replace, other cancer screening tests recommended by your doctor.
Consult with your doctor about your personal risk for cancer, and determine whether the TruCheck test is the right choice for you.
Once you request the TruCheck test, a doctor will review your information to ensure that the test is suitable for you. You will then have the option to either have a trained professional come to your home or office to take your blood sample, or you can opt to arrange this yourself. If the doctor determines that TruCheck is not suitable for you, you will receive a full refund.
⦁ You are aged 40 or over
⦁ You have no prior history of diagnosis or treatment of any type of cancer
⦁ You are not displaying any symptoms of cancer at this time
⦁ You have no clinical suspicion of cancer at this time
⦁ You have not had a blood transfusion in the past 72 hours
⦁ You consent to having a sample of your blood taken from you by a trained professional
You will be taken to our booking portal. You can choose to use Splitit when checking out to split the final payment into interest free installments.
The TruCheck test is suggested for use in adults with a higher risk of cancer, typically those aged 50 or above. TruCheck does not detect all types of cancers and should be considered a supplemental tool alongside routine cancer screening tests advised by your healthcare provider. The primary goal of TruCheck is to identify cancer signals and predict their origin within the body. It is not recommended for use in individuals who are pregnant, under the age of 40, or currently undergoing active cancer treatment.
Results must be analysed by a healthcare professional, taking into account the patient’s medical history, clinical signs, and symptoms. A result of “No Cancer Signal Detected” does not definitively exclude the presence of cancer. Likewise, a “Cancer Signal Detected” result necessitates further diagnostic evaluation through established medical procedures (such as imaging) to confirm the presence of cancer.
In cases where further testing does not confirm cancer, this could indicate either the absence of cancer or that the test was unable to detect it, including situations where the cancer is located in a different part of the body. Be aware that false-positive (a cancer signal detected when cancer is not present) and false-negative (a cancer signal not detected when cancer is present) results can occur.
1. Akolkar et al. B15: Circulating tumor cells express tissue specific antigens in multiple cancers. Clin Cancer Res.2020;
26(11_Suppl). DOI: 10.1158/1557-3265.LiqBiop20-B15.
2. Akolkar et al. Circulating ensembles of tumor-associated cells: A redoubtable new systemic hallmark of cancer. Int. J.
Cancer:2019; 146, 3485-3494. DOI: 10.1002/ijc.32815.
3. Gaya A et al. Evaluation of circulating tumor cell clusters for pan-cancer noninvasive diagnostic triaging. Cancer Cytopathol.
2020; 129 (3) 226-238 doi: 10.1002/cncy.22366.
4. Ranade A et al. Hallmark Circulating Tumor-Associated Cell Clusters Signify 230 Times Higher One-Year Cancer Risk. Cancer
Prev Res. 2021;14:11-6 DOI:10.1158/1940-6207.CAPR-20-0322.
5. Crook T et al. Accurate Screening for Early-Stage Breast Cancer by Detection and Profiling of Circulating Tumor Cells. Cancers
(Basel). 2022 Jul; 14(14): 3341. DOI: 10.3390/cancers14143341.
